Plain-English translation of NCT07358650 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This is one of the first times this treatment has been tested in people.
This is the first human study of the Hexiris MIST device, a new minimally invasive surgical tool designed to lower eye pressure in people with primary open-angle glaucoma. The procedure is performed at the slit lamp (a specialized eye microscope) using topical anesthesia, meaning numbing drops rather than general anesthesia. Researchers will follow you for 12 months after the procedure to see how safely and effectively the treatment works.
Many people with open-angle glaucoma don't achieve adequate eye pressure control with eye drops alone, which can lead to vision loss over time. This new treatment offers a less invasive alternative to traditional glaucoma surgery, aiming to help more patients safely reduce their eye pressure and preserve their sight.
You likely qualify if…
You likely don't qualify if…
The first five participants will have their procedure performed in an operating room for safety monitoring. After safety data is reviewed, the remaining participants may have the procedure performed at the slit lamp with numbing eye drops. You will receive the MIST device treatment along with an injection of a medication to prevent scarring, followed by antibiotic and steroid eye drops. You will then return for follow-up visits over the next 12 months, where researchers will check your eye pressure, vision, and overall eye health.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
Canada